Creative Planning’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-100
Closed -$989 3057
2023
Q2
$989 Buy
+100
New +$8.36K ﹤0.01% 2612
2022
Q4
Sell
-600
Closed -$2K 2620
2022
Q3
$2K Buy
600
+400
+200% +$33.7K ﹤0.01% 2292
2022
Q2
$2K Buy
+200
New +$15K ﹤0.01% 2258
2021
Q1
Sell
-200
Closed -$1K 2740
2020
Q4
$1K Sell
200
-100
-33% -$12.8K ﹤0.01% 2338
2020
Q3
$1K Sell
300
-300
-50% -$33.6K ﹤0.01% 2135
2020
Q2
$7K Buy
+600
New +$59.1K ﹤0.01% 1899

Other funds holding XBI

Creative Planning's XBI Position: Q2 2026 in Review

Creative Planning increased its State Street SPDR S&P Biotech ETF (XBI) stake by 16% in Q2 2026, buying an estimated $629K and bringing the position to 34,052 shares worth $5.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1353.

Creative Planning first reported a position in XBI in Q2 2013 and has held it in 52 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Creative Planning held 34,052 shares of State Street SPDR S&P Biotech ETF worth $5.39M as of Q2 2026.
  • Creative Planning bought 4,654 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $629K.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #1353 holding.
  • Creative Planning first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 52 quarters since.
  • 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.